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Abstract
Background: Acute kidney injury (AKI) is being increasingly recognised in ageing populations. There are a paucity
of data about AKI risk factors among older individuals with diabetes and infections, who are at particularly high risk
of AKI. The objective of this study was to evaluate the risk factors for developing acute kidney injury (AKI) amongst
older patients with diabetes and community-acquired pneumonia (CAP) in England, and whether the impact of
underlying kidney function varied with age.
Methods: This was a population-based retrospective cohort study over 7 years (01/04/2004–31/3/2011) using electronic
health records from the Clinical Practice Research Datalink linked to Hospital Episode Statistics. The study
population comprised individuals with diabetes aged ≥65 years with CAP. Associations between demographic,
lifestyle factors, co-morbidities and medications and development of AKI within 28 days of CAP were explored
in a logistic regression model.
Results: Among 3471 patients with CAP and complete covariate data, 298 patients developed subsequent AKI. In
multivariable analyses, factors found to be independently associated with AKI included: male sex (adjusted odds ratio,
aOR: 1.56 95% confidence interval (CI): 1.20–2.04), hypertension (aOR1.36 95% CI 1.01–1.85), being prescribed either
angiotensin-converting-enzyme inhibitors or angiotensin-II-receptor-blockers (aOR: 1.59 95% CI: 1.19–2.13), or insulin
(aOR: 2.27 95% CI: 1.27–4.05), presence of proteinuria (aOR 1.27 95% CI 0.98–1.63), and low estimated glomerular
filtration rate (eGFR). The odds of AKI were more graded amongst older participants aged ≥80 years compared to
those of younger age: for eGFR of ≤29 mL/min/1.73m2 (vs 60 ml/min/1.73m2) aOR: 5.51 95% CI 3.28–9.27 and for
eGFR 30–59 mL/min/1.73m2 1.96 95% CI 1.30–2.96, whilst any eGFR < 60 ml/min/1.73m2 was associated with
approximately 3-fold increase in the odds of AKI amongst younger individuals (p-value for interaction = 0.007).
Conclusions: The identified risk factors should help primary care and hospital providers identify high risk patients
in need of urgent management including more intensive monitoring, and prevention of AKI following pneumonia.
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Background
Acute kidney injury (AKI, a term introduced for
acute renal failure in 2004) is a clinical syndrome
of sudden renal impairment, and is associated with
adverse prognosis [1, 2]. The global incidence of
AKI in hospitalised adults reported in a 2013 meta-
analysis was ~22% with a mortality rate of ~24%
[3]. Other adverse outcomes associated with AKI
include end-stage renal disease, chronic kidney
disease (CKD) and a higher risk of cardio-vascular
events [4–6].
Risk factors for AKI include severe infections,
diabetes, older age and CKD [7, 8]. Older individuals
with diabetes are a group at particular risk of AKI
owing to multiple risk factors such as age, presence
of other co-morbidities including CKD, and predis-
position to serious infections [9]. A common infection
in this population group is community-acquired
pneumonia (CAP) [10–14], and a recent review [15]
reported rate ratios ranging from 1.5 to 3.1 for CAP
amongst people with diabetes compared to those
without diabetes. AKI triggered by infection, including
both severe and non-severe CAP, carries grave
prognosis with higher mortality and morbidity
requiring longer hospitalisation [16–19]. The conse-
quences of AKI in older people with diabetes who
develop pneumonia could be therefore severe, with
incomplete renal recovery [5, 6]. The reasons for
these adverse events following AKI amongst older
individuals with diabetes following pneumonia are
unclear. A study did not find differences in immune
marker levels amongst individuals with and without
diabetes following hospitalisation for CAP [20].
However, in this study mortality was high after CAP
especially in those with diabetes, and AKI was a
common problem [20]. The specific risk factors for AKI in
this high risk group have not been examined in previous
studies [19, 21–23].
The primary objective of this study was to deter-
mine risk factors for developing AKI within 28 days
of incident CAP in patients with diabetes aged
≥65 years in England. The secondary objective was to
assess whether any increased risk of AKI associated
with reduced estimated glomerular filtration rate
(eGFR) or proteinuria varied with age. The hypothesis
was that older participants with reduced eGFR may
be more predisposed to AKI compared to younger
individuals because of decreasing renal functional
reserve [24].
Methods
The data source for this study was the Clinical
Practice Research Datalink (CPRD) containing
anonymised patient records from UK general
practices covering ~7% of the population and
including cumulatively 79 million person-years of
follow-up [25, 26]. This longitudinal and quality-
assured database provides clinical, treatment,
laboratory, demographic and lifestyle information
for patients seen in primary care [26]. In England,
75% of CPRD general practices have consented to
linkages with hospitalisation data (Hospital Episode
Statistics, HES) and small-area level deprivation
data (Index of Multiple Deprivation, IMD) [26]. In
HES, the period between admission and discharge
is known as a ‘spell’ which comprises of one or
several episodes that are the periods of continuous
care from a single consultant. The record for each
spell is composed of a list of diagnoses occurring
during each episode of the patient’s admission [27].
This study is a subset of a large retrospective
cohort of older patients with diabetes, used to
investigate risks associated with CKD and infections
up to March 2011. Details of the overall study
population and the algorithms used to diagnose
CAP and other infections are published elsewhere
[28, 29]. For this study, the study population
comprised individuals aged ≥65 years with diabetes
mellitus in England whose general practices
consented to dataset linkages, and who had a first
diagnosis of CAP between April 2004 and March 2011.
The start date was chosen to ensure that the study
followed the introduction of the Quality and
Outcomes Framework in 2004 which standardised
management of chronic conditions in primary care
[30], and the introduction of consensus criteria for
AKI (also in 2004) [31]. Individuals who had a first
CAP diagnosis less than a year after they registered
with the practice were excluded, as these could be
historical episodes of CAP that were recorded
retrospectively in the first few months after
registration [32].
Outcome and exposure data
The outcome of interest was AKI diagnosed in
hospital, with the hospital episode start date within
28 days of the CAP diagnosis. This included
patients who were diagnosed and treated with CAP
in primary care; follow-up was not limited to
hospitalisation for CAP but included any admission
for AKI in the 28 days following CAP diagnosis.
The primary definition of AKI was a record in the
HES data coded with the specific International
Classification of Diseases-10 (ICD-10) code N17
(acute renal failure). Patients with either ICD-10
codes N17 or N19 (unspecified kidney failure) were
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used in sensitivity analyses to capture additional
patients with AKI who might have been coded with
the less specific ICD-10 code.
Potential risk factors for AKI identified in previous
studies were examined [19, 21, 33–37]. These
included older age, gender, body mass index (BMI),
deprivation (IMD), smoking status and alcohol intake;
nine co-morbidities: CKD, hypertension, congestive
cardiac failure, ischemic heart disease, cerebrovascular
disease, dementia, chronic lung disease, malignancies,
connective tissue disease and three medications: the
prescription of angiotensin converting enzyme inhibi-
tors (ACEI) and/or angiotensin II receptor blockers
(ARBs) prescribed within 6 months of CAP onset,
and lifetime history of anti-diabetes prescriptions (oral
hypoglycaemic drugs and/or insulin) prior to
infection. Socio-economic status was ascertained using
2007 Office for National Statistics’ IMD, a composite
area-level marker of deprivation categorised in quin-
tiles (1, least deprived; to 5, most deprived) [38]. Re-
cords with missing individual level IMD were
substituted with values for the relevant general practice.
All other risk factors were defined using primary care re-
cords in CPRD. The most recent glycated haemoglobin
level that was recorded at least 28 days prior to infection
onset (to describe baseline glycaemic control independent
of incipient CAP) was used. BMI was estimated using
the weight recorded closest to the CAP onset date
and categorised into underweight (<18.5 kg/m2), healthy
weight (18.5–24.9 kg/m2), overweight (25–29.9 kg/m2)
and obese (≥30 kg/m2). Similarly, smoking status
(non-, current or ex-smoker) and alcohol intake (non-,
ex-, current up to 6 units/day and heavy >6 units/day)
were ascertained using the last record prior to CAP onset
and if this was unavailable then the earliest record after
the infection onset were used. Diagnostic Read codes at
any time prior to CAP onset date were used to identify
the nine co-morbidities of interest, and prescription
records at any time prior to CAP onset for medica-
tion history. Underlying renal function was ascer-
tained from primary care records using either
estimated glomerular filtration rate (eGFR, from
laboratory reports) or presence of proteinuria without
urinary tract infection (from laboratory reports or
Read codes for proteinuria or proteinuric disease re-
corded by GPs), as detailed in our previous study
[39]. In brief, eGFR was based on the latest serum
creatinine result recorded prior to CAP onset
(excluding results recorded within 28 days of CAP
onset as these may reflect the effect of acute infec-
tion rather than pre-existing underlying renal func-
tion) and was estimated using the Chronic Kidney
Disease Epidemiology Collaboration equation adjusted
for ethnicity [40]. It was classified under three categories:
≥60, 30–59 and ≤29 mL/min/1.73m2 to maintain adequate
numbers in each group. Proteinuria was identified by a
positive urine protein test (without a concurrent urinary
tract infection), or by any Read code recording proteinuric
disease as previously described [39].
Data analysis
Individuals were followed up from the CAP diagnosis
date (the index date) until the earliest of: 28 days after
the CAP diagnosis, AKI diagnosis, patient’s death or
transfer out of the practice, the last date at which the
practice contributed data, the last HES linkage date,
initiation of renal replacement therapy (recorded in
either CPRD or HES) or 31/03/11.
Multivariable logistic regression was used to examine
the association of explanatory variables with presence or
absence of an AKI-code in the 28 days after CAP, using
odds ratios (OR) and 95% confidence interval (CI).
Individuals with complete covariate data were included
in analyses.
Age, gender and study-period were considered a
priori confounders as well as potential explanatory
variables in their own right. The study period split
into two categories, April 2004–September 2007 and
October 2007–March 2011, to assess the impact of
the Acute Kidney Injury Network (AKIN) criteria
introduced in 2007 [41]. The ORs for each explana-
tory variable were first examined in a minimally
adjusted model, adjusted for the three a priori
confounders. Hypothesis testing was conducted using
likelihood ratio test. Ordered categorical variables
such as eGFR, BMI, smoking-status, alcohol-intake
and the study-period were also examined for linear
trend.
A conceptual framework describing the hypothesised
hierarchy of risk factors for AKI was then developed
(Fig. 1) to inform the building of a multivariable
model to determine risk factors for AKI [19, 21, 33,
34, 36, 37]. Deprivation (IMD) was considered a distal
determinant [42], that mediates its effect first via life-
style factors (BMI, smoking and alcohol) and then via
more proximate determinants [42]: hypertension and
other co-morbidities, which themselves could act
partly via medications (Fig. 1). These variables were
added sequentially to the minimally adjusted model in
the order of their hypothesised position in the causal
pathway to AKI.
Being cautious about data sparsity and collinearity, the
number of variables included in the final model was
restricted to ensure at least ten outcomes per parameter
estimate [43]. If data sparsity was encountered the
decision for inclusion in the final model was based on
the magnitude of the effect estimates in the minimally
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adjusted model and P-values of <0.2. Collinearity was
assessed by comparing the log standard errors of the co-
efficients in the multivariable models.
An interaction of a priori interest, namely between
age and renal functional reserve was examined by
fitting the final multivariable model first with
interaction terms between age and eGFR and then
between age and proteinuria. Age was re-categorised
as a binary variable to examine effect modification
(65–79 years and ≥80 years) and models with and
without interaction terms were compared using the
likelihood ratio tests.
Three sensitivity analyses were conducted: (1) an
analysis including individuals who were excluded
from the primary analysis because of missing data,
dropping selected variables with missing data; (2)
repeating analyses after categorising AKI using both
ICD-10 N19 and N17 codes, to capture non-specific
coding for AKI; and (3) repeating the final
multivariable analyses for only those individuals
who were hospitalised within 28 days (for any
reason) of CAP diagnosis to minimise ascertain-
ment bias of AKI.
Results
The study population included a total of 4115 pa-
tients with CAP, of whom 346 (8.4%) had AKI. Data
were missing for five variables (Table 1): BMI (7.6%),
alcohol-intake (7.5%), HbA1C (4.7%), eGFR (1.2%)
and smoking-status (0.5%); data on individual IMD
were available for 91.1% of individuals, with IMD for
the general practice used for the remaining 8.9%.
The complete case analyses included 3471
patients, with 298 (8.6%) cases of AKI. Most (3047/
3471 (87.8%)) of the patients with CAP were
hospitalised. A comparison of patients included
and excluded from analysis is shown in Table 1.
Briefly, those included in analysis were more likely
to be males, younger, ex-smokers, current alcohol-
consumers and with raised BMI. They were also
more likely to have records of proteinuria,
hypertension and ischaemic heart disease and to
have been prescribed ACEI or ARBs or anti-
diabetic medications, but were less likely to have
dementia.
Minimally adjusted analysis
In the analysis adjusted for age, gender and study
period (Table 2 column 2), there was little evidence
of an association between most demographic and
lifestyle factors (age, deprivation, smoking and
alcohol intake) and AKI, except for increased odds of
AKI amongst males and the most obese individuals
(BMI ≥30 kg/m2). More AKI diagnoses were
observed in the second half of study period. Amongst
the nine co-morbidities examined as risk factors, the
odds for AKI in patients with hypertension was 1.6
times higher compared to those without hyperten-
sion. There was also very strong evidence for an
association with underlying renal function: there was
a linear trend in increasing odds of AKI with
decreasing eGFR, with those with eGFR ≤ 29 at more
than five times the odds of AKI, and those with
proteinuria at 1.7 times the odds of AKI. In contrast,
there was some evidence for reduced odds for AKI
among those with connective tissue disease and
cancer. For medication, higher odds of AKI were
observed amongst patients taking either ACEI/ARB,
and among those prescribed insulin. Due to concerns
about data-sparsity, IMD (the least strongly associ-
ated variable in this analysis) was dropped from
further models.
Multivariable analysis
The multivariable models were built sequentially as
described in the Methods. After adjusting for
lifestyle and socio-demographic factors (Table 4 in
Appendix) and then for hypertension, and then
other co-morbidities (Model 4: Table 2, column 4),
the increased odds associated with hypertension
persisted and the linear increased odds of AKI with
Fig. 1 Hypothesized conceptual hierarchical framework for risk factors
for acute kidney injury
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Table 1 Baseline characteristics of patients included and excluded from analyses (2004–2011)
Characteristics Patients included in analysis Patients excluded from analysis
Total N = 3471 With AKI = 298 Total N = 644 With AKI = 48
Females 1558 (44.9) 113 (37.9) 384 (59.6) 25 (52.1)
Age (years) 65–69 414 (11.9) 31 (10.4) 53 (8.2) 3 (6.3)
70–74 587 (16.9) 39 (13.1) 66 (10.3) 4 (8.3)
75–79 725 (20.9) 60 (20.1) 100 (15.5) 6 (12.5)
80–84 810 (23.3) 72 (24.2) 141 (21.9) 14 (29.2)
≥85 935 (26.9) 96 (32.2) 284 (44.1) 21 (43.8)
IMDa 1 (least deprived) 575 (16.6) 48 (16.1) 102 (15.8) 6 (12.5)
2 808 (23.3) 72 (24.2) 166 (25.8) 17 (35.4)
3 742 (21.4) 63 (21.1) 141 (21.9) 11 (22.9)
4 756 (21.8) 67 (22.5) 124 (19.3) 7 (14.6)
5 (most deprived) 590 (17.0) 48 (16.1) 111 (17.2) 7 (14.6)
Smoking status Non-smoker 851 (24.5) 64 (21.5) 275 (42.7) 20 (41.7)
Current smoker 634 (18.3) 53 (17.8) 94 (14.6) 6 (12.5)
Ex-smoker 1986 (57.2) 181 (60.7) 253 (39.3) 20 (41.7)
Missing 0 (0.0) 0 (0.0) 22 (3.4) 2 (4.2)
Alcohol intake u/day Non-drinker 517 (14.9) 45 (15.1) 83 (12.9) 10 (20.8)
Ex-drinker 530 (15.3) 53 (17.8) 38 (5.9) 4 (8.3)
Current ≤6 units/day 2281 (65.7) 192 (64.4) 199 (30.9) 7 (14.6)
Heavy >6 units/day 143 (4.1) 8 (2.7) 17 (2.6) 4 (8.3)
Missing 0 (0.0) 0 (0.0) 307 (47.7) 23 (47.9)
BMI categories (kg/m2) 15–18.4 126 (3.6) 9 (3.0) 23 (3.6) 1 (2.1)
18.5–24.9 1177 (33.9) 97 (32.6) 110 (17.1) 8 (16.7)
25–29.9 1173 (33.8) 93 (31.2) 123 (19.1) 13 (27.1)
≥30 995 (28.7) 99 (33.2) 77 (12.0) 6 (12.5)
Missing 0 (0.0) 0 (0.0) 311 (48.3) 20 (41.7)
eGFR (mL/min/1.73m2) ≤29 280 (8.1) 54 (18.1) 46 (7.1) 8 (16.7)
30–59 1487 (42.8) 165 (55.4) 262 (40.7) 19 (39.6)
≥60 1704 (49.1) 79 (26.5) 288 (44.7) 19 (39.6)
Missing 0 (0.0) 0 (0.0) 48 (7.5) 2 (4.2)
Proteinuria 1326 (38.2) 152 (51.0) 109 (16.9) 11 (22.9)
Hypertension 2450 (70.6) 236 (79.2) 368 (57.1) 31 (64.6)
Congestive cardiac failure 743 (21.4) 74 (24.8) 119 (18.5) 7 (14.6)
Ischaemic heart disease 1326 (38.2) 108 (36.2) 167 (25.9) 11 (22.9)
Cerebrovascular diseases 919 (26.5) 80 (26.9) 189 (29.4) 18 (37.5)
Dementia 239 (6.9) 23 (7.7) 107 (16.6) 7 (14.6)
Chronic lung disease 895 (25.8) 67 (22.5) 143 (22.2) 13 (27.1)
Cancer 638 (18.4) 46 (15.4) 112 (17.4) 6 (12.5)
Connective tissue diseases 329 (9.5) 19 (6.4) 58 (9.0) 4 (8.3)
ACEIs 1603 (46.2) 164 (55.0) 212 (32.9) 25 (52.1)
ARBs 579 (16.7) 70 (23.5) 45 (7.0) 3 (6.2)
Either ACEIs/ ARBs 2105 (60.7) 220 (73.8) 253 (39.3) 27 (56.2)
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reducing eGFR were still observed. However, the
previously observed strong evidence of higher odds
of AKI with proteinuria was reduced (P = 0.07) and
the association of high BMI with AKI seen in the
previous model disappeared.
In the final multivariable analysis (Model 5: Table 2
column 6), ACEI/ARB users had 60% increased odds
of AKI after adjusting for the other co-morbidities
and lifestyle factors. The increased risk of AKI with
insulin use remained. The previously observed
association of AKI with BMI, hypertension and
proteinuria was attenuated after adjusting for these
additional mediating variables. There was evidence
of lower odds of AKI amongst patients with
ischemic heart disease.
Effect modification by age
Table 3 shows the age-specific ORs for the
association of AKI with eGFR and proteinuria as
markers of CKD. There was strong evidence
(Pinteraction = 0.007) of an interaction between age
and eGFR after adjusting for other risk factors for
AKI, with a more pronounced effect of
eGFR < 30 mL/min/1.73m2 on AKI amongst those
aged ≥80 years (adjusted-OR 5.51 95% CI 3.28–9.27)
compared to the younger group (adjusted-OR 2.90
95%CI 1.46–5.77). In the older individuals (aged
≥80 years) the graded increase in odds of AKI with
decreasing eGFR remained but this graded
association was not evident in the younger age-
group for whom any eGFR < 60 ml/min/1.73m2 was
associated with an approximately three fold increase
in AKI risk (Table 3).
In contrast, there was little evidence (Pinteraction = 0.34)
that the effect of proteinuria on AKI varied by age.
Sensitivity analyses (Tables 5, 6 and 7 in Appendix)
After excluding the four variables with missing data that
had less strong evidence of an association with AKI
(smoking status, alcohol intake, BMI and HbA1C) there
were 4067 individuals included in the analysis. The
results from this model were similar to those of the
main model (Table 5 in Appendix).
After widening the definition of AKI to include the
non-specific N19 code, the number of patients who
developed AKI increased from 298 (coded only as ICD-
10 N17) to 373 (coded either ICD-10 N17 or N19). The
lower odds associated with connective tissue diseases
was no longer apparent in this model, but no other ap-
preciable changes were evident (Table 6 in Appendix).
Amongst those hospitalised the overall risk of
developing AKI was 9.8% (N = 298). Results after
restricting analyses to those who were hospitalised
were very similar to those in the entire study popula-
tion (Table 7 in Appendix).
Discussion
Amongst older individuals with diabetes and CAP
the overall risk for AKI within 28 days of incident
CAP diagnosis was 8.4% for the entire cohort and
9.8% amongst those who were hospitalised. The risk
factors independently associated with AKI were
male sex, reduced eGFR, absence of ischemic heart
disease, use of ACEIs/ARBs and insulin. The associ-
ation of hypertension and proteinuria with AKI
attenuated after adjusting for ACEIs/ARBs use. The
association of reducing eGFR with AKI was found
to be more prominent amongst individuals aged
≥80 years, whilst any eGFR < 60 ml/min/1.73m2
was associated with AKI risk amongst younger
study participants.
Table 1 Baseline characteristics of patients included and excluded from analyses (2004–2011) (Continued)
HBA1C Good <7% 1887 (54.4) 163 (54.7) 278 (43.2) 20 (41.7)
Borderline 7–10% 1427 (41.1) 122 (40.9) 146 (22.7) 12 (25.0)
High >10% 157 (4.5) 13 (4.4) 25 (3.9) 4 (8.3)
Missing 0 (0.0) 0 (0.0) 195 (30.3) 12 (25.0)
Medication-diabetes None 859 (24.8) 64 (21.5) 270 (41.9) 18 (37.5)
Oral 1802 (51.9) 144 (48.3) 264 (41.0) 20 (41.7)
Insulin 142 (4.1) 22 (7.4) 43 (6.7) 4 (8.3)
Both 668 (19.3) 68 (22.8) 67 (10.4) 6 (12.5)
Study period April 2004- Sep.2007 1325 (38.2) 57 (19.1) 331 (51.4) 12 (25.0)
Oct.2007-March 2011 2146 (61.8) 241 (80.9) 313 (48.6) 36 (75.0)
(%) column percentages IMD index of multiple deprivation a8.9% records with missing individual index of multiple deprivation were substituted by values for
general practice u units; BMI body mass index, eGFR estimated glomerular filtration rate, ACEIs angiotensin converting enzyme inhibitors, ARBs angiotensin II
receptor blockers, HBA1C glycated-haemoglobin levels Sep. September Oct. October
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Table 2 Multivariable analyses of the association of risk factors and acute kidney injury (N = 3471)
Characteristics Model 1 adjusted for
age, sex and period
OR (95% CI)
P valuea
(PT)
Model 4c adjusted for all
variables in table except
IMD, medications and HBA1C
OR (95% CI)
P valuea
(PT)
Model 5 additionally
adjusted for medications
& HBA1C
OR (95% CI)
P valuea
(PT)
Females 0.71 (0.56–0.91) 0.007 0.63 (0.48–0.82) 0.0005 0.64 (0.49–0.83) 0.0008
Age years 65–69 0.67 (0.44–1.03) 0.11 0.92 (0.57–1.48) 0.74 0.83 (0.52–1.35) 0.55
70–74 0.62 (0.42–0.92) 0.76 (0.50–1.17) 0.70 (0.46–1.09)
75–79 0.75 (0.53–1.06) 0.83 (0.57–1.20) 0.78 (0.54–1.13)
80–84 0.84 (0.61–1.17) 0.88 (0.63–1.24) 0.84 (0.59–1.18)
≥85 1 1 1
IMDb 1 (least deprived) 1 Not in model Not in model
2 1.09 (0.74–1.60) 0.96
3 1.07 (0.72–1.59)
4 1.16 (0.78–1.72)
5 (most
deprived)
1.06 (0.69–1.61)
Smoking status Non-smoker 1 1 1
Current smoker 1.12 (0.76–1.67) 0.74 1.32 (0.87–2.00) 0.36 1.39 (0.92–2.11) 0.25
Ex-smoker 1.13 (0.83–1.53) 1.22 (0.88–1.68) 1.26 (0.91–1.74)
Alcohol intake
(u/day)
Non-drinker 1 1 1
Ex-drinker 0.98 (0.64–1.50) 0.27 1.00 (0.65–1.55) 0.40 1.00 (0.64–1.55) 0.43
Current
≤6 units/day
0.83 (0.59–1.18) 0.86 (0.60–1.23) 0.88 (0.61–1.26)
Heavy
>6 units/day
0.52 (0.24–1.15) 0.56 (0.25–1.26) 0.55 (0.24–1.26)
BMI (kg/m2) 15–18.4 0.80 (0.39–1.64) 0.05 0.90 (0.43–1.88) 0.50 0.95 (0.45–2.00) 0.53
18.5–24.9 1 1 1
25–29.9 1.00 (0.74–1.35) 0.92 (0.67–1.25) 0.90 (0.65–1.23)
≥30 1.44 (1.05–1.97) 1.17 (0.85–1.62) 1.14 (0.82–1.58)
eGFR
(mL/min/1.73m2)
≤29 5.53 (3.75–8.15) <0.0001 4.80 (3.18–7.23) <0.0001 4.62 (3.06–6.99) <0.0001
30–59 2.74 (2.06–3.66) (<0.0001) 2.58 (1.92–3.47) (<0.0001) 2.48 (1.84–3.33) (<0.0001)
≥60 1 1 1
Proteinuria 1.66 (1.30–2.11) <0.0001 1.27 (0.98–1.63) 0.07 1.23 (0.95–1.59) 0.12
Hypertension 1.63 (1.21–2.19) 0.0007 1.36 (1.01–1.85) 0.04 1.27 (0.93–1.73) 0.13
Congestive cardiac failure 1.24 (0.94–1.64) 0.13 1.07 (0.79–1.45) 0.65 1.03 (0.76–1.39) 0.86
Ischaemic heart disease 0.90 (0.70–1.15) 0.4 0.79 (0.61–1.03) 0.08 0.76 (0.58–1.00) 0.04
Cerebrovascular diseases 1.00 (0.76–1.31) 0.99 0.90 (0.68–1.19) 0.44 0.90 (0.68–1.20) 0.47
Dementia 1.05 (0.66–1.65) 0.85 1.12 (0.70–1.80) 0.64 1.17 (0.73–1.88) 0.53
Chronic lung disease 0.79 (0.59–1.06) 0.11 0.79 (0.59–1.07) 0.12 0.79 (0.58–1.07) 0.12
Cancer 0.72 (0.52–1.01) 0.05 0.73 (0.52–1.03) 0.07 0.76 (0.54–1.07) 0.11
Connective tissue diseases 0.63 (0.39–1.01) 0.04 0.64 (0.39–1.05) 0.06 0.66 (0.40–1.08) 0.08
Either ACEIs/ ARBs 1.96 (1.49–2.58) <0.0001 Not in model 1.59 (1.19–2.13) 0.002
HBA1C levels Good <7% 1 Not in model 1
Borderline 7–10% 1.01 (0.79–1.30) 0.98 0.82 (0.62–1.09) 0.38
High >7% 0.95 (0.52–1.73) 0.82 (0.43–1.54)
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The risk of 9.8% found in this cohort is lower
than that reported by a Scottish study [23] that
found AKI incidence of 18% amongst CAP patients
at time of hospital admission. Another study [19]
reported AKI incidence of 34% any time during
hospitalisation in CAP patients aged ≥18 years. In
both these studies the diagnosis of CAP was con-
firmed in the hospital and were not confined to in-
dividuals with diabetes [19, 23]. In the present
study CAP diagnosis in general practice (which is
mainly a clinical diagnosis) could have led to a
higher study denominator and perhaps an under-
estimation of the risk of AKI.
A temporal change in increased AKI diagnosis
during the period of 2007–2011, as observed in
previous studies using CPRD and HES [44, 45] was
also evident in this study, reflecting better ascertain-
ment of outcome in the latter period. In the earlier
period of the study, coded AKI events are likely to
have been for the more serious forms of AKI [46].
This is not necessarily a draw-back as the analyses
identifies those at highest risk of more severe AKI.
The validation of recording of AKI (during 2005 and
2010) in UK hospital data has been previously
described [44] with a high positive predictive value
(95%) for AKI codes in these data.
Table 2 Multivariable analyses of the association of risk factors and acute kidney injury (N = 3471) (Continued)
Medication
diabetes
None 1 Not in model 1
Oral 1.10 (0.81–1.50) 0.005 1.05 (0.75–1.46) 0.05
Insulin 2.49 (1.46–4.23) 2.27 (1.27–4.05)
Both 1.43 (0.99–2.07) 1.11 (0.72–1.71)
Period April 2004-
Sep. 2007
1 <0.0001 1 <0.0001 1 <0.0001
Oct. 2007-
March 2011
2.79 (2.07–3.76) (<0.0001) 2.91 (2.14–3.94) (<0.0001) 2.90 (2.14–3.95) (<0.0001)
IMD index of multiple deprivation OR odds ratio CI confidence interval alikelihood ratio test PT P value for trend
brecords with missing individual IMD were
substituted by values for general practice cModel 2 and 3 are presented in Table 4 in Appendix u units; BMI body mass index, eGFR estimated glomerular filtration rate,
ACEI angiotensin converting enzyme inhibitors, ARBs angiotensin II receptor blockers Sep. September Oct. October
Table 3 Association of pre-existing eGFR and proteinuria with acute kidney injury stratified by age (N = 3471)
eGFR
(mL/min/1.73m2)
Total With AKI
N (%)
Stratum-specific adjusteda
OR for acute kidney injury (95%CI)
P-value for
interactionb
Age 65–79 ≤29 102 13 (12.8) 2.90 (1.46–5.77) 0.007
30–59 586 74 (12.6) 3.29 (2.20–4.94)
≥60 1038 43 (4.1) 1
Total 1726 130 (7.5)
Age 80 or above ≤29 178 41 (23) 5.51 (3.28–9.27)
30–59 901 91 (10.1) 1.96 (1.30–2.96)
≥60 666 36 (5.4) 1
Total 1745 168 (9.6)
Proteinuria Total With AKI
N (%)
Stratum-specific adjusteda
OR for acute kidney injury (95%CI)
P-value for
interactionb
Age 65–79 No 1057 57 (5.4) 1 0.34
Yes 669 73 (10.9) 1.42 (0.96–2.08)
Total 1726 130 (7.5)
Age 80 or above No 1088 89 (8.2) 1
Yes 657 79 (12) 1.11 (0.79–1.55)
Total 1745 168 (9.6)
AKI acute kidney injury (%) row percentage eGFR estimated glomerular filtration rate aModel 5 in Table 2
OR odds ratio CI confidence interval blikelihood ratio test
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The association of two markers of CKD: reducing
eGFR and presence of proteinuria were identified as
independent risk factors for AKI as previously
reported for the general population [47, 48]. We
found that age modified the strength of association
of reduced eGFR with AKI risk: amongst study par-
ticipants <80 years of age any reduced eGFR was
associated with AKI risk, whilst amongst older
study participants those with eGFR < 30 ml/min/
1.73m2 were especially at risk of AKI. Once eGFR
was added to the model, age no longer had a statis-
tically independent association, except through the
observed effect modification. There was no
evidence of interaction of age with proteinuria as
has been described previously for the general
population [48]. Other risk factors identified in this
study with AKI included male gender, BMI ≥30 kg/m2,
hypertension and use of ACEIs & ARBs, as previously
reported for the general population [8, 37, 49], for
individuals with diabetes [33] and amongst patients
with infections and septic shock [36, 45]. Amongst
patients on insulin without oral antiglycaemic
medications, it could be hypothesized that patients
taking insulin alone were more likely to have Type-I
diabetes with a longer disease duration affecting
renal-vasculature. However, reliable data on disease
duration or type were not available in this dataset
and so these aspects of diabetes could not be
explored in this study.
This was a population based large cohort study
using quality-assured data from the UK general
practices spanning a 7-year study period and
describes for the first time the factors associated
with AKI in this patient population. The use of
conceptual framework allowed explanation of
possible mediating pathways between risk factors
and AKI and independent assessment of the associ-
ation of both eGFR and history of proteinuria with
AKI. The results are potentially generalizable to
older patients with diabetes and CAP from other
similar-income countries to England with similar
demographic profile and access to healthcare.
This study has the limitations from using routinely
collected data. Due to the nature of dataset the association
of severity of CAP with AKI could not be assessed.
Another potential limitation was missing data;
complete data were available for 84.3% participants
and a sensitivity analysis conducted to minimise the
effect of missing data using data from 98.8% of
these participants showed no noticeable differences
from the primary analyses. Other potential risk
factors such as ethnicity, hyperlipidaemia, duration
of diabetes and antibiotic use were not measured so
the effect-estimates may have residual confounding.
Competing risk of death may have played a role as
approximately 30% of study participants died within
28 days after the CAP diagnosis [50]. Because an
eGFR of <30 ml/min/1.73m2 is known to be
associated with death after admission, the associa-
tions seen in this analysis are likely to have been
underestimated for the lower eGFR risk group, and
could be potentially even higher than we have
shown [50]. A competing risk approach would have
been particularly appropriate if we had wanted to
develop a predictive risk score. However, at this
stage we wished simply to understand causality
(potential risk factors in this high risk group) [51].
We did not have data on the presentation of CAP –
the hospital coding variables depend on coding in
discharge letters and the clinical presentation is not
captured by the diagnostic ICD10 codes in the HES
database. We did not use the latest available serum
creatinine prior to CAP diagnosis, as we wanted to
capture the underlying renal function irrespective
of the context of the acute infection, and because
test results may not have been available for every
patient except for those who were most ill. Most
people with diabetes require careful adaptation of
diabetes drugs in the context of altered glucose
control during infection. These data are observa-
tional and the association seen with ACEIs/ARBs
may be due to underlying confounding by
indication. Those who are prescribed these drugs
have typically higher blood pressure, or are more
proteinuric, or have heart failure [52]. The standard
ACEIs/ARBs prescribed in primary care have a long
pharmacological half life [53]; stopping these in the
context of infection means that these drugs may
stay up to 7 days in the body. Therefore, whilst it
is true that people who are on these drugs are at
higher risk, it is not clear whether sick-day rules
that advise stopping the drugs would indeed
prevent AKI in the week following infection.
Evaluation of this via a clinical trial would help to
elucidate the potential benefits of stopping ACEIs/
ARBs in this setting.
Conclusions
In summary, amongst older people with diabetes who
are diagnosed with CAP, risk of AKI is largely
dependent on pre-existing renal function with age
modifying this relationship, and prescription of insulin
and/or ACE-I/ARB, as well as male sex. The identified
risk factors should help primary care and hospital
providers identify those patients with CAP who should
be monitored more closely (for example, with timely
administration of antibiotics and appropriate fluid
management) to prevent AKI following pneumonia.
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Appendix
Table 4 Multivariable analyses of the association between risk factors and acute kidney injury: three Models (N = 3471)
Characteristics Model 1
Adjusted for age,
sex and period
OR (95% CI)
P valuea
(PT)
Model 2 additionally,
adjusted for BMI, smoking,
alcohol-intake
OR (95% CI)
P valuea
(PT)
Model 3 additionally
adjusted for hypertension
OR (95% CI)
P valuea
(PT)
Females 0.71 (0.56–0.91) 0.007 0.69 (0.53–0.89) 0.004 0.66 (0.51–0.86) 0.002
Age categories
years
65–69 0.67 (0.44–1.03) 0.11 0.59 (0.37–0.92) 0.02 0.59 (0.37–0.92) 0.03
70–74 0.62 (0.42–0.92) 0.55 (0.36–0.83) 0.55 (0.36–0.83)
75–79 0.75 (0.53–1.06) 0.68 (0.48–0.97) 0.66 (0.46–0.94)
80–84 0.84 (0.61–1.17) 0.80 (0.58–1.12) 0.78 (0.56–1.09)
≥85 1 1 1
Estimated IMDb 1
(least deprived)
1 Not in model Not in model
2 1.09 (0.74–1.60) 0.96
3 1.07 (0.72–1.59)
4 1.16 (0.78–1.72)
5
(most deprived)
1.06 (0.69–1.61)
Smoking status Non-smoker 1 1 1
Current smoker 1.12 (0.76–1.67) 0.74 1.17 (0.78–1.74) 0.68 1.18 (0.79–1.77) 0.65
Ex-smoker 1.13 (0.83–1.53) 1.14 (0.83–1.55) 1.14 (0.83–1.56)
Alcohol intake
(units/day)
Non-drinker 1 1 1
Ex-drinker 0.98 (0.64–1.50) 0.27 0.97 (0.63–1.49) 0.29 0.96 (0.63–1.48) 0.24
Current
≤6 units/day
0.83 (0.59–1.18) 0.83 (0.58–1.18) 0.82 (0.58–1.17)
Heavy
>6 units/day
0.52 (0.24–1.15) 0.53 (0.24–1.17) 0.50 (0.23–1.11)
BMI (kg/m2) 15–18.4 0.80 (0.39–1.64) 0.05 0.80 (0.39–1.63) 0.06 0.80 (0.39–1.64) 0.09
18.5–24.9 1 1 1
25–29.9 1.00 (0.74–1.35) 1.00 (0.74–1.36) 0.99 (0.73–1.34)
≥30 1.44 (1.05–1.97) 1.43 (1.04–1.95) 1.39 (1.01–1.90)
eGFR
(mL/min/1.73m2)
≤29 5.53 (3.75–8.15) <0.0001 Not in model Not in model
30–59 2.74 (2.06–3.66) (<0.0001)
≥60 1
Proteinuria 1.66 (1.30–2.11) <0.0001 Not in model Not in model
Hypertension 1.63 (1.21–2.19) 0.0007 Not in model 1.62 (1.21–2.18) 0.0009
Congestive cardiac
failure
1.24 (0.94–1.64) 0.13 Not in model Not in model
Ischaemic heart disease 0.90 (0.70–1.15) 0.4 Not in model Not in model
Cerebrovascular
diseases
1.00 (0.76–1.31) 0.99 Not in model Not in model
Dementia 1.05 (0.66–1.65) 0.85 Not in model Not in model
Chronic lung disease 0.79 (0.59–1.06) 0.11 Not in model Not in model
Cancer 0.72 (0.52–1.01) 0.05 Not in model Not in model
Connective tissue
disease
0.63 (0.39–1.01) 0.04 Not in model Not in model
Either ACEIs/ ARBs 1.96 (1.49–2.58) <0.0001 Not in model Not in model
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Table 4 Multivariable analyses of the association between risk factors and acute kidney injury: three Models (N = 3471) (Continued)
HbA1C Good <7% 1 Not in model Not in model
Borderline
7–10%
1.01 (0.79–1.30) 0.98
High >7% 0.95 (0.52–1.73)
Medication
diabetes
None 1 Not in model Not in model
Oral 1.10 (0.81–1.50) 0.005
Insulin 2.49 (1.46–4.23)
Both 1.43 (0.99–2.07)
Study period April2004-
September 2007
1 <0.0001 1 <0.0001 1 <0.0001
October2007-
March 2011
2.79 (2.07–3.76) (<0.0001) 2.78 (2.06–3.75) (<0.0001) 2.72 (2.01–3.66) (<0.0001)
OR odds ratio CI confidence interval alikelihood ratio test PT P value for trend IMD index of multiple deprivation
brecords with missing individual IMD were
substituted by values for general practice u/d units/day BMI body mass index eGFR estimated glomerular filtration rate ACEI angiotensin converting enzyme
inhibitors ARBs angiotensin II receptor blockers
Table 5 Sensitivity analysis 1: Association of risk factors and acute kidney injury: multivariable analysis excluding smoking status,
alcohol intake, body mass index and glycated-haemoglobin levels (N = 4067, outcome = 344)
Characteristics Model from primary analysisa
Odds ratio (95% confidence interval)
P valuec (PT) Sensitivity analysis
Odds ratiob
(95% confidence interval)
P valuec (PT)
Females 0.64 (0.49–0.83) 0.0008 0.64 (0.51–0.82) 0.0003
Age categories (years) 65–69 0.83 (0.52–1.35) 0.55 0.85 (0.55–1.31) 0.64
70–74 0.70 (0.46–1.09) 0.75 (0.51–1.12)
75–79 0.78 (0.54–1.13) 0.82 (0.58–1.15)
80–84 0.84 (0.59–1.18) 0.93 (0.68–1.26)
≥85 1 1
Smoking status Non-smoker 1 Not in model
Current smoker 1.39 (0.92–2.11) 0.25
Ex-smoker 1.26 (0.91–1.74)
Alcohol intake (units/day) Non-drinker 1 Not in model
Ex-drinker 1.00 (0.64–1.55) 0.43
Current ≤6 units/day 0.88 (0.61–1.26)
Heavy >6 units/day 0.55 (0.24–1.26)
BMI (kg/m2) 15–18.4 0.95 (0.45–2.00) 0.53 Not in model
18.5–24.9 1
25–29.9 0.90 (0.65–1.23)
≥30 1.14 (0.82–1.58)
eGFR (mL/min/1.73m2): ≤29 4.62 (3.06–6.99) <0.0001 4.43 (3.03–6.46) <0.0001
30–59 2.48 (1.84–3.33) (<0.0001) 2.21 (1.68–2.90) (<0.0001)
≥60 1 1
Proteinuria 1.23 (0.95–1.59) 0.12 1.22 (0.96–1.56) 0.10
Hypertension 1.27 (0.93–1.73) 0.13 1.17 (0.89–1.55) 0.26
Congestive cardiac failure 1.03 (0.76–1.39) 0.86 0.97 (0.73–1.29) 0.83
Ischaemic heart disease 0.76 (0.58–1.00) 0.04 0.77 (0.60–0.98) 0.03
Cerebrovascular diseases 0.90 (0.68–1.20) 0.47 0.96 (0.74–1.24) 0.74
Dementia 1.17 (0.73–1.88) 0.53 1.10 (0.73–1.67) 0.65
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Table 5 Sensitivity analysis 1: Association of risk factors and acute kidney injury: multivariable analysis excluding smoking status,
alcohol intake, body mass index and glycated-haemoglobin levels (N = 4067, outcome = 344) (Continued)
Chronic lung disease 0.79 (0.58–1.07) 0.12 0.90 (0.68–1.18) 0.43
Cancer 0.76 (0.54–1.07) 0.11 0.73 (0.53–1.01) 0.05
Connective tissue diseases 0.66 (0.40–1.08) 0.08 0.68 (0.43–1.07) 0.08
Either ACEI/ARBs 1.59 (1.19–2.13) 0.002 1.66 (1.27–2.17) 0.0001
HBA1C levels Good <7% 1 Not in model
Borderline 7–10% 0.82 (0.62–1.09) 0.38
High >7% 0.82 (0.43–1.54)
Medication diabetes None 1 1
Oral 1.05 (0.75–1.46) 0.05 1.00 (0.74–1.33) 0.08
Insulin 2.27 (1.27–4.05) 1.89 (1.14–3.11)
Both 1.11 (0.72–1.71) 1.03 (0.72–1.47)
Study period April 2004–September 2007 1 <0.0001 1 <0.0001
October 2007–March 2011 2.90 (2.14–3.95) (<0.0001) 2.94 (2.22–3.89) (<0.0001)
aadjusted for age, sex, study period, smoking status, alcohol intake, BMI, comorbidities, medications and glycated-haemoglobin levels badjusted for all variables in
the table except smoking, alcohol intake, BMI and glycated haemoglobin levelsclikelihood ratio test PT P value for trend BMI body mass index eGFR estimated
glomerular filtration rate ACEI angiotensin converting enzyme inhibitors ARBs angiotensin II receptor blockers
Table 6 Sensitivity analysis 2: Risk factors associated with acute kidney injury multivariable model with ICD10-N17 or N19 code for
outcome (N = 3471 outcome = 373)
Characteristics Model from primary analysisa
OR (95% CI)
P valueb (PT) Sensitivity analysis
Odds Ratioa
(95% confidence interval)
P valueb (PT)
Females 0.64 (0.49–0.83) 0.0008 0.63 (0.49–0.80) 0.0002
Age categories years 65–69 0.83 (0.52–1.35) 0.55 1.00 (0.65–1.54) 0.52
70–74 0.70 (0.46–1.09) 0.75 (0.50–1.11)
75–79 0.78 (0.54–1.13) 0.82 (0.58–1.15)
80–84 0.84 (0.59–1.18) 0.90 (0.66–1.23)
≥85 1 1
Smoking status Non-smoker 1 0.25 1 0.32
Current smoker 1.39 (0.92–2.11) 1.32 (0.91–1.92)
Ex-smoker 1.26 (0.91–1.74) 1.19 (0.89–1.59)
Alcohol intake (units/day) Non-drinker 1 0.43 1 0.18
Ex-drinker 1.00 (0.64–1.55) 1.17 (0.78–1.76)
Current ≤6 units/day 0.88 (0.61–1.26) 0.99 (0.71–1.39)
Heavy >6 units/day 0.55 (0.24–1.26) 0.54 (0.25–1.16)
BMI (kg/m2) 15–18.4 0.95 (0.45–2.00) 0.53 0.80 (0.40–1.61) 0.28
18.5–24.9 1 1
25–29.9 0.90 (0.65–1.23) 0.84 (0.63–1.11)
≥30 1.14 (0.82–1.58) 1.10 (0.81–1.47)
eGFR (mL/min/1.73m2) ≤29 4.62 (3.06–6.99) <0.0001 4.86 (3.34–7.09) <0.0001
30–59 2.48 (1.84–3.33) (<0.0001) 2.47 (1.89–3.23) (<0.0001)
≥60 1 1
Proteinuria 1.23 (0.95–1.59) 0.12 1.22 (0.96–1.54) 0.10
Hypertension 1.27 (0.93–1.73) 0.13 1.19 (0.90–1.57) 0.21
Congestive cardiac failure 1.03 (0.76–1.39) 0.86 1.05 (0.80–1.39) 0.71
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Table 6 Sensitivity analysis 2: Risk factors associated with acute kidney injury multivariable model with ICD10-N17 or N19 code for
outcome (N = 3471 outcome = 373) (Continued)
Ischaemic heart disease 0.76 (0.58–1.00) 0.04 0.77 (0.60–0.98) 0.03
Cerebrovascular disease 0.90 (0.68–1.20) 0.47 0.81 (0.62–1.05) 0.10
Dementia 1.17 (0.73–1.88) 0.53 1.17 (0.76–1.82) 0.48
Chronic lung disease 0.79 (0.58–1.07) 0.12 0.75 (0.57–0.98) 0.03
Cancer 0.76 (0.54–1.07) 0.11 0.89 (0.66–1.19) 0.42
Connective tissue diseases 0.66 (0.40–1.08) 0.08 0.73 (0.47–1.12) 0.14
Either ACEI/ ARBs 1.59 (1.19–2.13) 0.002 1.48 (1.14–1.92) 0.003
Glycated haemoglobin levels Good <7% 1 1
Borderline 7–10% 0.82 (0.62–1.09) 0.38 0.85 (0.66–1.10) 0.42
High >7% 0.82 (0.43–1.54) 1.03 (0.60–1.77)
Medication-diabetes None 1 1
Oral 1.05 (0.75–1.46) 0.05 1.02 (0.75–1.38) 0.02
Insulin 2.27 (1.27–4.05) 2.27 (1.34–3.84)
Both 1.11 (0.72–1.71) 1.10 (0.74–1.62)
Study period April 2004–September 2007 1 <0.0001 1 <0.0001
October 2007–March 2011 2.90 (2.14–3.95) (<0.0001) 2.38 (1.83–3.10) (<0.0001)
aadjusted for all variables in table BMI body mass index eGFR estimated glomerular filtration rate ACEI angiotensin converting enzyme inhibitors ARBs angiotensin
II receptor blockersb likelihood ratio test PT P value for trend
Table 7 Sensitivity analysis 3: Risk factors associated with acute kidney injury multivariable model restricted to hospitalised patients
(N = 3047 outcome = 298)
Characteristics Primary analysis
OR (95% CI)b
P valuea (PT) Sensitivity analysis
OR (95% CI)b
P valuea (PT)
Gender Female 0.64 (0.49–0.83) 0.0008 0.64 (0.49–0.84) 0.001
Age categories years 65–69 0.83 (0.52–1.35) 0.55 0.84 (0.52–1.37) 0.49
70–74 0.70 (0.46–1.09) 0.70 (0.45–1.09)
75–79 0.78 (0.54–1.13) 0.75 (0.52–1.10)
80–84 0.84 (0.59–1.18) 0.82 (0.58–1.16)
≥85 1 1
Smoking status Non-smoker 1 0.25 1 0.32
Current smoker 1.39 (0.92–2.11) 1.34 (0.88–2.04)
Ex-smoker 1.26 (0.91–1.74) 1.25 (0.90–1.73)
Alcohol intake (units/day) Non-drinker 1 0.43 1 0.59
Ex-drinker 1.00 (0.64–1.55) 1.00 (0.64–1.56)
Current ≤6 units/day 0.88 (0.61–1.26) 0.88 (0.61–1.28)
Heavy >6 units/day 0.55 (0.24–1.26) 0.61 (0.27–1.40)
BMI (kg/m2) 15–18.4 0.95 (0.45–2.00) 0.53 1.00 (0.47–2.13) 0.56
18.5–24.9 1 1
25–29.9 0.90 (0.65–1.23) 0.89 (0.65–1.22)
≥30 1.14 (0.82–1.58) 1.12 (0.80–1.56)
eGFR (mL/min/1.73m2) ≤29 4.62 (3.06–6.99) <0.0001 4.54 (2.98–6.90) <0.0001
30–59 2.48 (1.84–3.33) (<0.0001) 2.40 (1.78–3.25) (<0.0001)
≥60 1 1
Proteinuria 1.23 (0.95–1.59) 0.12 1.19 (0.92–1.55) 0.19
Hypertension 1.27 (0.93–1.73) 0.13 1.30 (0.95–1.78) 0.09
Jain et al. BMC Nephrology  (2017) 18:142 Page 13 of 16
Abbreviations
ACEI: Angiotensin converting enzyme inhibitor; AKI: Acute kidney injury;
AKIN: Acute Kidney Injury Network; aOR: Adjusted odds ratio;
ARB: Angiotensin II receptor blocker; BMI: Body mass index;
CAP: Community-acquired pneumonia; CI: Confidence interval; CKD: Chronic
kidney disease; CPRD: Clinical Practice Research Datalink; eGFR: Estimated
glomerular filtration rate; HbA1C: Glycated-haemoglobin; HES: Hospital
Episode Statistics; ICD: International Classification of Diseases; IMD: Index of
Multiple Deprivation; KDIGO: Kidney Disease: Improving Global outcomes;
OR: Odds ratio
Acknowledgements
None.
Funding
This work was supported by the National Institute for Health Research [CDF
2010–03-32 to S.L.T.] and Kidney Research UK [ST2/2011 to H.I.M.]. LT is funded
by a Wellcome Trust Intermediate Clinical Fellowship (101,143/Z/13/Z).
The funders of the study had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript. The views
expressed in this publication are those of the authors and not necessarily
those of the UK National Health Service, the National Institute for Health
Research, the Department of Health nor Kidney Research UK.
Availability of data and materials
The data that support the findings of this study were used under licence
and belong to the Clinical Practice Research Datalink, and so are not publicly
available. We will therefore ultimately be governed in respect of data sharing
by the data owners: any requests to share will be subject to their permission,
and to the approval of the ethics committees overseeing the use of these
data sources.
Authors’ contributions
AJ planned and conducted the analysis, interpretation of data and drafted
the manuscript. HIM supported the data extraction and cleaning. SLT, DN, LT
and HIM made substantial contribution to study design. All authors
contributed to and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
This study was approved by the Independent Scientific Advisory Group of
MHRA (ISAC reference 11_033AMn) and the London School of Hygiene and
Tropical Medicine Ethics Committee (LSHTM reference 6116).
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Received: 17 November 2016 Accepted: 22 April 2017
References
1. Kidney Disease: Improving global outcomes (KDIGO) acute kidney injury
working group. KDIGO clinical practice guideline for acute kidney injury.
Kidney Int Suppl (2012). 2012;2(1):1-138. doi:10.1038/kisup.2012.3.
2. Mehta RL, Bouchard J, Soroko SB, Ikizler TA, Paganini EP, Chertow GM, et al.
Sepsis as a cause and consequence of acute kidney injury: program to
improve Care in Acute Renal Disease. Intensive Care Med. 2011;37(2):241–8.
doi:10.1007/s00134-010-2089-9.
3. Susantitaphong P, Cruz DN, Cerda J, Abulfaraj M, Alqahtani F, Koulouridis I,
et al. World incidence of AKI: a meta-analysis. Clin J Am Soc Nephrol. 2013;
8(9):1482–93. doi:10.2215/CJN.00710113.
4. Coca SG, Cho KC, Hsu CY. Acute kidney injury in the elderly: predisposition
to chronic kidney disease and vice versa. Nephron Clin Pract. 2011;
119(Suppl 1):c19–24. doi:10.1159/000328023.
5. Ishani A, Xue JL, Himmelfarb J, Eggers PW, Kimmel PL, Molitoris BA, et al.
Acute kidney injury increases risk of ESRD among elderly. J Am Soc Nephrol.
2009;20(1):223–8. doi:10.1681/ASN.2007080837.
Table 7 Sensitivity analysis 3: Risk factors associated with acute kidney injury multivariable model restricted to hospitalised patients
(N = 3047 outcome = 298) (Continued)
Congestive cardiac failure 1.03 (0.76–1.39) 0.86 1.06 (0.78–1.43) 0.73
Ischaemic heart disease 0.76 (0.58–1.00) 0.04 0.75 (0.57–0.98) 0.03
Cerebrovascular disease 0.90 (0.68–1.20) 0.47 0.89 (0.67–1.19) 0.44
Dementia 1.17 (0.73–1.88) 0.53 1.26 (0.78–2.04) 0.36
Chronic lung disease 0.79 (0.58–1.07) 0.12 0.76 (0.56–1.03) 0.08
Cancer 0.76 (0.54–1.07) 0.11 0.77 (0.55–1.09) 0.13
Connective tissue diseases 0.66 (0.40–1.08) 0.08 0.64 (0.39–1.05) 0.07
Either ACEI/ ARBs 1.59 (1.19–2.13) 0.002 1.57 (1.17–2.11) 0.002
Glycated haemoglobin levels Good <7% 1 1
Borderline 7–10% 0.82 (0.62–1.09) 0.38 0.83 (0.62–1.10) 0.40
High >7% 0.82 (0.43–1.54) 0.82 (0.43–1.56)
Medication-diabetes None 1 0.05 1 0.03
Oral 1.05 (0.75–1.46) 1.05 (0.75–1.48)
Insulin 2.27 (1.27–4.05) 2.43 (1.34–4.40)
Both 1.11 (0.72–1.71) 1.11 (0.72–1.71)
Study period April 2004–September 2007 1 <0.0001 1 <0.0001
(<0.0001)
October 2007–March 2011 2.90 (2.14–3.95) (<0.0001) 2.74 (2.01–3.73) (<0.0001)
OR odds ratio CI confidence interval alikelihood ratio test PT P value for trend
badjusted for all variables in table BMI body mass index eGFR estimated
glomerular filtration rate ACEI angiotensin converting enzyme inhibitors ARBs angiotensin II receptor blockers Sep. September Oct. October
Jain et al. BMC Nephrology  (2017) 18:142 Page 14 of 16
6. Schmitt R, Coca S, Kanbay M, Tinetti ME, Cantley LG, Parikh CR. Recovery of
kidney function after acute kidney injury in the elderly: a systematic review
and meta-analysis. Am J Kidney Dis. 2008;52(2):262–71. doi:10.1053/j.ajkd.
2008.03.005.
7. Ali T, Khan I, Simpson W, Prescott G, Townend J, Smith W, et al. Incidence
and outcomes in acute kidney injury: a comprehensive population-based
study. J Am Soc Nephrol. 2007;18(4):1292–8. doi:10.1681/ASN.2006070756.
8. Leblanc M, Kellum JA, Gibney RT, Lieberthal W, Tumlin J, Mehta R. Risk
factors for acute renal failure: inherent and modifiable risks. Curr Opin Crit
Care. 2005;11(6):533–6.
9. Shah BR, Hux JE. Quantifying the risk of infectious diseases for people with
diabetes. Diabetes Care. 2003;26(2):510–3.
10. Ljubic S, Balachandran A, Pavlic-Renar I, Barada A, Metelko Z. Pulmonary
infections in diabetes mellitus. Diabetol Croat. 2005;33(4):115–24.
11. Ruben FL, Dearwater SR, Norden CW, Kuller LH, Gartner K, Shalley A, et al.
Clinical infections in the noninstitutionalized geriatric age group: methods
utilized and incidence of infections. The Pittsburgh Good health study. Am J
Epidemiol. 1995;141(2):145–57.
12. Koivula I, Sten M, Makela PH. Risk factors for pneumonia in the elderly. Am J
Med. 1994;96(4):313–20.
13. Jackson ML, Neuzil KM, Thompson WW, Shay DK, Yu O, Hanson CA, et al. The
burden of community-acquired pneumonia in seniors: results of a population-
based study. Clin Infect Dis. 2004;39(11):1642–50. doi:10.1086/425615.
14. Kornum JB, Thomsen RW, Riis A, Lervang HH, Schonheyder HC, Sorensen
HT. Diabetes, glycemic control, and risk of hospitalization with pneumonia:
a population-based case-control study. Diabetes Care. 2008;31(8):1541–5.
doi:10.2337/dc08-0138.
15. Torres A, Blasi F, Dartois N, Akova M. Which individuals are at increased risk
of pneumococcal disease and why? Impact of COPD, asthma, smoking,
diabetes, and/or chronic heart disease on community-acquired pneumonia
and invasive pneumococcal disease. Thorax. 2015;70(10):984–9. doi:10.1136/
thoraxjnl-2015-206780.
16. Bagshaw SM, Lapinsky S, Dial S, Arabi Y, Dodek P, Wood G, et al. Acute
kidney injury in septic shock: clinical outcomes and impact of duration of
hypotension prior to initiation of antimicrobial therapy. Intensive Care Med.
2009;35(5):871–81. doi:10.1007/s00134-008-1367-2.
17. Bagshaw SM, Uchino S, Bellomo R, Morimatsu H, Morgera S, Schetz M, et al.
Septic acute kidney injury in critically ill patients: clinical characteristics and
outcomes. Clin J Am Soc Nephrol. 2007;2(3):431–9. doi:10.2215/CJN.03681106.
18. Neveu H, Kleinknecht D, Brivet F, Loirat P, Landais P. Prognostic factors in
acute renal failure due to sepsis. Results of a prospective multicentre study.
The French study group on acute renal failure. Nephrol Dial Transplant.
1996;11(2):293–9.
19. Murugan R, Karajala-Subramanyam V, Lee M, Yende S, Kong L, Carter M,
et al. Acute kidney injury in non-severe pneumonia is associated with
an increased immune response and lower survival. Kidney Int. 2010;
77(6):527–35. doi:10.1038/ki.2009.502.
20. Yende S, van der Poll T, Lee M, Huang DT, Newman AB, Kong L, et al. The
influence of pre-existing diabetes mellitus on the host immune response
and outcome of pneumonia: analysis of two multicentre cohort studies.
Thorax. 2010;65(10):870–7. doi:10.1136/thx.2010.136317.
21. Breidthardt T, Christ-Crain M, Stolz D, Bingisser R, Drexler B, Klima T, et al. A
combined cardiorenal assessment for the prediction of acute kidney injury
in lower respiratory tract infections. Am J Med. 2012;125(2):168–75.
22. Chiu PF, Huang CH, Liou HH, Wu CL, Wang SC, Chang CC. Long-term renal
outcomes of episodic urinary tract infection in diabetic patients. J Diabetes
Complicat. 2013;27(1):41–3. doi:10.1016/j.jdiacomp.2012.08.005.
23. Akram AR, Singanayagam A, Choudhury G, Mandal P, Chalmers JD, Hill AT.
Incidence and prognostic implications of acute kidney injury on admission
in patients with community-acquired pneumonia. Chest. 2010;138(4):825–
32. doi:10.1378/chest.09-3071.
24. Musso CG, Liakopoulos V, Ioannidis I, Eleftheriadis T, Stefanidis I. Acute renal
failure in the elderly: particular characteristics. Int Urol Nephrol. 2006;38(3–4):
787–93. doi:10.1007/s11255-006-0084-4.
25. CPRD. The Clinical Practice Research Datalink. 2014. http://www.cprd.com/
intro.asp. Accessed 28 Aug 2014.
26. Herrett E, Gallagher AM, Bhaskaran K, Forbes H, Mathur R, van Staa T, et al.
Data resource profile: clinical practice Research Datalink (CPRD). Int J
Epidemiol. 2015; doi:10.1093/ije/dyv098.
27. Health and Social Care Information Centre. Hospital Episode Statistics. 2014.
http://www.hscic.gov.uk/hes. Accessed 28 Aug 2014.
28. McDonald HI, Nitsch D, Millett ER, Sinclair A, Thomas SL. New estimates of
the burden of acute community-acquired infections among older people
with diabetes mellitus: a retrospective cohort study using linked electronic
health records. Diabet Med. 2013; doi:10.1111/dme.12384.
29. Millett ER, Quint JK, Smeeth L, Daniel RM, Thomas SL. Incidence of
community-acquired lower respiratory tract infections and pneumonia
among older adults in the United Kingdom: a population-based study. PLoS
One. 2013;8(9):e75131. doi:10.1371/journal.pone.0075131.
30. The Information Centre. Online GP practice results database. Quality and
Outcomes Framework 2005/06 for GP practices 2006. http://www.qof.ic.nhs.
uk/0506/. Accessed 18 Aug 2014.
31. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute dialysis quality
initiative w. Acute renal failure - definition, outcome measures, animal
models, fluid therapy and information technology needs: the second
International consensus conference of the acute dialysis quality initiative
(ADQI) group. Crit Care. 2004;8(4):R204–12. doi:10.1186/cc2872.
32. Lewis JD, Bilker WB, Weinstein RB, Strom BL. The relationship between time
since registration and measured incidence rates in the general practice
Research database. Pharmacoepidemiol Drug Saf. 2005;14(7):443–51. doi:10.
1002/pds.1115.
33. Girman CJ, Kou TD, Brodovicz K, Alexander CM, O'Neill EA, Engel S, et al.
Risk of acute renal failure in patients with type 2 diabetes mellitus. Diabet
Med. 2012;29(5):614–21. doi:10.1111/j.1464-5491.2011.03498.x.
34. Mittalhenkle A, Stehman-Breen CO, Shlipak MG, Fried LF, Katz R, Young BA,
et al. Cardiovascular risk factors and incident acute renal failure in older
adults: the cardiovascular health study. Clin J Am Soc Nephrol. 2008;3(2):
450–6. doi:10.2215/CJN.02610607.
35. National Institute for Health and Care Excellence. Acute kidney injury:
prevention, detection and management of acute kidney injury up to the
point of renal replacement therapy. (Clinical guideline 169)2013.
36. Plataki M, Kashani K, Cabello-Garza J, Maldonado F, Kashyap R, Kor DJ, et al.
Predictors of acute kidney injury in septic shock patients: an observational
cohort study. Clin J Am Soc Nephrol. 2011;6(7):1744–51. doi:10.2215/CJN.
05480610.
37. Rewa O, Bagshaw SM. Acute kidney injury-epidemiology, outcomes and
economics. Nat Rev Nephrol. 2014;10(4):193–207. doi:10.1038/nrneph.2013.282.
38. Office of National Statistics. 2011 Rural-Urban Classification for small
area geographies. 2011. http://www.ons.gov.uk/ons/guide-method/
geography/products/area-classifications/2011-rural-urban/index.html.
Accessed 02 Feb 2014.
39. McDonald HI, Thomas SL, Millett ER, Nitsch D. CKD and the risk of acute,
community-acquired infections among older people with diabetes mellitus:
a retrospective cohort study using electronic health records. Am J Kidney
Dis. 2015;66(1):60–8. doi:10.1053/j.ajkd.2014.11.027.
40. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et
al. A new equation to estimate glomerular filtration rate. Ann Intern Med.
2009;150(9):604–12.
41. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, et al.
Acute kidney injury Network: report of an initiative to improve outcomes in
acute kidney injury. Crit Care. 2007;11(2):R31. doi:10.1186/cc5713.
42. Victora CG, Huttly SR, Fuchs SC, Olinto MT. The role of conceptual
frameworks in epidemiological analysis: a hierarchical approach. Int J
Epidemiol. 1997;26(1):224–7.
43. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study
of the number of events per variable in logistic regression analysis. J Clin
Epidemiol. 1996;49(12):1373–9.
44. Tomlinson LA, Riding AM, Payne RA, Abel GA, Tomson CR, Wilkinson IB.
The accuracy of diagnostic coding for acute kidney injury in England - a
single centre study. BMC Nephrol. 2013;14 doi:10.1186/1471-2369-14-58.
45. Iwagami M, Mansfield K, Quint J, Nitsch D, Tomlinson L. Diagnosis of
acute kidney injury and its association with in-hospital mortality in
patients with infective exacerbations of bronchiectasis: cohort study
from a UK nationwide database. BMC Pulm Med. 2016;16(1):1–8. doi:10.
1186/s12890-016-0177-5.
46. Kolhe NV, Muirhead AW, Wilkes SR, Fluck RJ, Taal MW. The epidemiology of
hospitalised acute kidney injury not requiring dialysis in England from 1998
to 2013: retrospective analysis of hospital episode statistics. Int J Clin Pract.
2016;70(4):330–9. doi:10.1111/ijcp.12774.
47. Hsu C, Ordonez J, Chertow G, Fan D, McCulloch C, Go A. The risk of acute
renal failure in patients with chronic kidney disease. Kidney Int.
2008;74(1):101–7.
Jain et al. BMC Nephrology  (2017) 18:142 Page 15 of 16
48. Grams ME, Astor BC, Bash LD, Matsushita K, Wang Y, Coresh J. Albuminuria
and estimated glomerular filtration rate independently associate with acute
kidney injury. J Am Soc Nephrol. 2010;21(10):1757–64. doi:10.1681/ASN.
2010010128.
49. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury
Working Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury.
Online Appendices A-F. 2012. http://www.kdigo.org/clinical_practice_
guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F_March2012.pdf. Accessed
04 Sept 2014.
50. McDonald HI, Nitsch D, Millett ER, Sinclair A, Thomas SL. Are pre-existing
markers of chronic kidney disease associated with short-term mortality
following acute community-acquired pneumonia and sepsis? A cohort
study among older people with diabetes using electronic health records.
Nephrol Dial Transplant. 2015;30(6):1002–9. doi:10.1093/ndt/gfu401.
51. Noordzij M, Leffondré K, van Stralen KJ, Zoccali C, Dekker FW, Jager KJ.
When do we need competing risks methods for survival analysis in
nephrology? Nephrol Dial Transplant. 2013;28(11):2670–7.
52. Mansfield KE, Nitsch D, Smeeth L, Bhaskaran K, Tomlinson LA. Prescription of
renin–angiotensin system blockers and risk of acute kidney injury: a
population-based cohort study. BMJ Open. 2016;6(12). doi:10.1136/
bmjopen-2016-012690.
53. British National Formulary. Drugs affecting the renin-angiotensin system
2017. https://www.evidence.nhs.uk/formulary/bnf/current/2-cardiovascular-
system/25-hypertension-and-heart-failure/255-drugs-affecting-the-renin-
angiotensin-system. Accessed 26 Feb 2017.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Jain et al. BMC Nephrology  (2017) 18:142 Page 16 of 16
